FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384030306> ?p ?o ?g. }

• W4384030306 endingPage "100845" @default.
• W4384030306 startingPage "100845" @default.
• W4384030306 abstract "Background and aimsOxidative stress triggers metabolic fatty liver disease (MAFLD) and fibrosis. Previous animal studies demonstrated that the transcription factor NRF2, the master regulator of antioxidant response, protects against MAFLD and fibrosis. S217879, a next generation NRF2 activator has been recently shown to trigger diet-induced steatohepatitis resolution and to reduce established fibrosis in rodents. Our aim was to evaluate the therapeutic potential of S217879 in human MAFLD and its underlying mechanisms using the relevant experimental 3D model of patient-derived precision cut liver slices (PCLS).MethodsWe treated PCLS from 12 patients with varying stages of MAFLD with S217879 or Elafibranor (PPARα/δ agonist used as a referent molecule) for two days. Safety and efficacy profiles, steatosis, liver injury, inflammation and fibrosis were assessed as well as mechanisms involved in MAFLD pathophysiology, namely antioxidant response, autophagy and ER-stress.ResultsNeither Elafibranor nor S217879 had toxic effects at the tested concentrations on human PCLS with MAFLD. PPARα/δ and NRF2 target genes (PDK4, FGF21 and NQO1, HMOX1, respectively) were strongly upregulated in PCLS in response to Elafibranor and S217879, respectively. Compared to untreated PCLS, Elafibranor and S217879-treated slices displayed lower triglycerides and reduced inflammation (IL-1β, IL-6, CCL2). Additional inflammatory markers (CCL5, STING, ICAM-1, VCAM-1) were downregulated by S217879. S217879 but not Elafibranor lowered DNA damages (p-H2A.X, RAD51, XRCC1) and apoptosis (cleaved Caspase-3), and inhibited fibrogenesis markers expression (α-SMA, COL1A1, COL1A2). Such effects were mediated through an improvement of lipid metabolism, activated antioxidant response and enhanced autophagy, without effect on ER-stress.ConclusionThis study highlights the therapeutic potential of a new NRF2 activator for MAFLD using patient-derived PCLS supporting the evaluation of NRF2 activating strategies in clinical trials." @default.
• W4384030306 created "2023-07-13" @default.
• W4384030306 creator A5005674434 @default.
• W4384030306 creator A5029905059 @default.
• W4384030306 creator A5031172542 @default.
• W4384030306 creator A5037535042 @default.
• W4384030306 creator A5037716296 @default.
• W4384030306 creator A5044373565 @default.
• W4384030306 creator A5048710140 @default.
• W4384030306 creator A5052729782 @default.
• W4384030306 creator A5056474348 @default.
• W4384030306 date "2023-10-01" @default.
• W4384030306 modified "2023-10-14" @default.
• W4384030306 title "A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease" @default.
• W4384030306 cites W1554837601 @default.
• W4384030306 cites W1963521777 @default.
• W4384030306 cites W1972662172 @default.
• W4384030306 cites W1974702375 @default.
• W4384030306 cites W1979086975 @default.
• W4384030306 cites W2011605334 @default.
• W4384030306 cites W2022598304 @default.
• W4384030306 cites W2023503151 @default.
• W4384030306 cites W2034298464 @default.
• W4384030306 cites W2035676834 @default.
• W4384030306 cites W2048989237 @default.
• W4384030306 cites W2062059387 @default.
• W4384030306 cites W2062522914 @default.
• W4384030306 cites W2065880243 @default.
• W4384030306 cites W2068037459 @default.
• W4384030306 cites W2070968982 @default.
• W4384030306 cites W2092700213 @default.
• W4384030306 cites W2097500515 @default.
• W4384030306 cites W2098462984 @default.
• W4384030306 cites W2100097928 @default.
• W4384030306 cites W2100877123 @default.
• W4384030306 cites W2133584350 @default.
• W4384030306 cites W2142855123 @default.
• W4384030306 cites W2153253838 @default.
• W4384030306 cites W2154111720 @default.
• W4384030306 cites W2164672742 @default.
• W4384030306 cites W2170075604 @default.
• W4384030306 cites W2171218310 @default.
• W4384030306 cites W2253420963 @default.
• W4384030306 cites W2287836528 @default.
• W4384030306 cites W2318256082 @default.
• W4384030306 cites W2327865165 @default.
• W4384030306 cites W2734724639 @default.
• W4384030306 cites W2744982526 @default.
• W4384030306 cites W2759997926 @default.
• W4384030306 cites W2765786596 @default.
• W4384030306 cites W2775505129 @default.
• W4384030306 cites W2783806692 @default.
• W4384030306 cites W2794139372 @default.
• W4384030306 cites W2804042123 @default.
• W4384030306 cites W2805997803 @default.
• W4384030306 cites W2807938853 @default.
• W4384030306 cites W2810423511 @default.
• W4384030306 cites W2884945282 @default.
• W4384030306 cites W2891103014 @default.
• W4384030306 cites W2894123970 @default.
• W4384030306 cites W2899595328 @default.
• W4384030306 cites W2902912681 @default.
• W4384030306 cites W2910830636 @default.
• W4384030306 cites W2914225706 @default.
• W4384030306 cites W2917099874 @default.
• W4384030306 cites W2934946727 @default.
• W4384030306 cites W2948704259 @default.
• W4384030306 cites W2955615964 @default.
• W4384030306 cites W2988672227 @default.
• W4384030306 cites W3004644667 @default.
• W4384030306 cites W3008423815 @default.
• W4384030306 cites W3094270956 @default.
• W4384030306 cites W3117083078 @default.
• W4384030306 cites W3126379854 @default.
• W4384030306 cites W3134583129 @default.
• W4384030306 cites W3144960635 @default.
• W4384030306 cites W3152939216 @default.
• W4384030306 cites W3160163020 @default.
• W4384030306 cites W3174901789 @default.
• W4384030306 cites W3175868564 @default.
• W4384030306 cites W4200269321 @default.
• W4384030306 cites W4200584065 @default.
• W4384030306 cites W4283706065 @default.
• W4384030306 cites W4311904534 @default.
• W4384030306 cites W4365138277 @default.
• W4384030306 doi "https://doi.org/10.1016/j.jhepr.2023.100845" @default.
• W4384030306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37663119" @default.
• W4384030306 hasPublicationYear "2023" @default.
• W4384030306 type Work @default.
• W4384030306 citedByCount "0" @default.
• W4384030306 crossrefType "journal-article" @default.
• W4384030306 hasAuthorship W4384030306A5005674434 @default.
• W4384030306 hasAuthorship W4384030306A5029905059 @default.
• W4384030306 hasAuthorship W4384030306A5031172542 @default.
• W4384030306 hasAuthorship W4384030306A5037535042 @default.
• W4384030306 hasAuthorship W4384030306A5037716296 @default.
• W4384030306 hasAuthorship W4384030306A5044373565 @default.
• W4384030306 hasAuthorship W4384030306A5048710140 @default.

• next